These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33806619)

  • 1. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
    Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
    Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM
    Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555
    [No Abstract]   [Full Text] [Related]  

  • 11. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
    Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
    Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
    Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
    Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
    Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Bhatt S; Pioso MS; Olesinski EA; Yilma B; Ryan JA; Mashaka T; Leutz B; Adamia S; Zhu H; Kuang Y; Mogili A; Louissaint A; Bohl SR; Kim AS; Mehta AK; Sanghavi S; Wang Y; Morris E; Halilovic E; Paweletz CP; Weinstock DM; Garcia JS; Letai A
    Cancer Cell; 2020 Dec; 38(6):872-890.e6. PubMed ID: 33217342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways and mechanisms of venetoclax resistance.
    Bose P; Gandhi V; Konopleva M
    Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 18. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
    Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
    Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.